MSWA
CMPX icon

Marshall & Sterling Wealth Advisors’s Compass Therapeutics CMPX Stock Holding History

Marshall & Sterling Wealth Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06K Hold
200
– – ﹤0.01% 309
2025
Q4 		$1.07K Hold
200
– – ﹤0.01% 305
2025
Q3 		$700 Hold
200
– – ﹤0.01% 612
2025
Q2 		$520 Hold
200
– – ﹤0.01% 607
2025
Q1 		$380 Hold
200
– – ﹤0.01% 623
2024
Q4 		$290 Buy
+200
New +$332 ﹤0.01% 350

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall & Sterling Wealth Advisors's CMPX Position: Q1 2026 in Review

Marshall & Sterling Wealth Advisors held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 200 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #309.

Marshall & Sterling Wealth Advisors first reported a position in CMPX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.07K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Marshall & Sterling Wealth Advisors held 200 shares of Compass Therapeutics worth $1.06K as of Q1 2026.
  • Marshall & Sterling Wealth Advisors left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Marshall & Sterling Wealth Advisors's portfolio in Q1 2026, its #309 holding.
  • Marshall & Sterling Wealth Advisors first reported a position in Compass Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Marshall & Sterling Wealth Advisors's Compass Therapeutics position peaked at $1.07K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Marshall & Sterling Wealth Advisors's 13F filing for Q1 2026, filed 7 May 2026.